Capricor Therapeutics

We just reported our fourth quarter and full year 2025 financial results. Click here to read the release: bit.ly/4bKdCcP Our quarterly conference call begins at 4:30 p.m. ET – join the webcast here: bit.ly/3NjKRLy $CAPR #DMD #Deramiocel

Yesterday at #MDA2026, we presented late-breaking data from the Phase 3 HOPE-3 trial highlighting Deramiocel’s potential impact on functional outcomes in Duchenne muscular dystrophy. Read the full release: bit.ly/3NfTTcE $CAPR #DMD #Deramiocel

We’re pleased to be attending the 2026 MDA Conference this week in Orlando, Florida. This important meeting brings together clinicians, researchers and patient advocates to discuss the latest developments in Duchenne muscular dystrophy (DMD) and other neuromuscular diseases. Capricor will be featured in the late-breaking presentation on March 11 and will also be at Booth #407 during the meeting. If you’re attending, please stop by and say hello. #MDA2026 $CAPR #MuscularDystrophy #DMD #Deramiocel

Today we announced that the U.S. FDA has resumed review of our BLA for Deramiocel for the treatment of Duchenne muscular dystrophy and set a PDUFA target action date of August 22, 2026. Click here to read the announcement: bit.ly/4bz2qk2 #DMD #Deramiocel $CAPR

February 28 is Rare Disease Day 💜 Today, we stand with the more than 300 million people worldwide living with a rare disease — including those affected by Duchenne muscular dystrophy (DMD). At Capricor, our mission is clear: advance innovative therapies and work with urgency to bring new options to patients and families who need them most. Today and every day, we remain focused on transforming innovation into hope. #RareDiseaseDay #DMD #RareButNotAlone $CAPR

We are pleased to share that Capricor has been selected for a late-breaking oral presentation at the 2026 MDA Clinical & Scientific Conference featuring our Phase 3 HOPE-3 results, alongside the submission of the HOPE-3 clinical study report to the U.S. FDA in support of our ongoing BLA review. To read the full announcement, click here: bit.ly/4cLtDB9 $CAPR #DMD #MDAconference #MuscularDystrophy #HopeForDMD

We are pleased to provide a regulatory update on Deramiocel following FDA review of the HOPE-3 topline data. The FDA has requested the HOPE-3 clinical study report, an expected step as the BLA review progresses. Click to read the release: bit.ly/4b8MiWU $CAPR #DMD #Dearamiocel

Our CEO, Linda Marbán, joined Amy Brown on @BiotechTV at the JPM Healthcare Conference to reflect on a meaningful year for our Duchenne muscular dystrophy program. The conversation highlights key milestones for Deramiocel, including the Phase 3 HOPE-3 readout as well as next steps in the regulatory review and what this progress could mean for individuals and families in the DMD community. Watch the full interview here: biotechtv.com/post/capricor-… $CAPR #JPM2026 #JPM26 #JPMHealthcare #Deramiocel #DMD

In case you missed it: Parent Project Muscular Dystrophy and Capricor hosted a community webinar discussing positive topline results from the Phase 3 HOPE-3 trial evaluating Deramiocel in Duchenne muscular dystrophy, including a review of the data and how the findings inform ongoing regulatory discussions and next steps with the FDA. Catch the webinar replay here: bit.ly/4p6zt2L $CAPR #PPMD #HOPE3 #DMD #Deramiocel

Today at 1:00 p.m. ET Join @PPMD and Capricor for a community webinar discussing positive topline results from the Phase 3 HOPE-3 trial evaluating Deramiocel in DMD. We’ll review the data and discuss how the findings inform ongoing regulatory discussions, including next steps with the FDA. Read the press release: bit.ly/3KWo3jY Register here: bit.ly/3KMGNCt $CAPR #PPMD #HOPE3 #DMD #Deramiocel

Today marks a defining moment for the Duchenne community. The U.S. Department of Health and Human Services has added Duchenne muscular dystrophy to the Recommended Uniform Screening Panel, expanding newborn screening nationwide—an important step toward earlier diagnosis and improved outcomes for families. We are proud to stand alongside the community as this progress continues. $CAPR #DMD #Deramiocel #NewbornScreening

Capricor is pleased to be participating today in the Oppenheimer Movers in Rare Disease Summit in New York. We will be featured on a rare disease panel and participating in a series of one-on-one meetings to discuss our recent progress and the path ahead. $CAPR #DMD #Deramiocel #RareDisease

Thank you to everyone who joined our conference call and webcast yesterday to review the positive topline results from our pivotal Phase 3 HOPE-3 study of Deramiocel. Interest in the event was exceptionally high, and due to the unusually heavy traffic, our webcast platform experienced intermittent delays that may have prevented some viewers from accessing the full live stream. The full replay and presentation slides are now available on our website here. bit.ly/4pObKor $CAPR #HOPE3 #Deramiocel #DMD #RareDisease

Following this morning’s announcement of positive topline results from our pivotal Phase 3 HOPE-3 clinical study, Capricor will be presenting today at the Piper Sandler 37th Annual Healthcare Conference. We will be featured in a fireside chat starting at 11:30 a.m. ET. To access the live webcast, click here bit.ly/49Pz3d3 $CAPR #HOPE3 #Deramiocel #DMD

Breaking: Capricor is extremely pleased to announce positive topline results from our pivotal Phase 3 HOPE-3 clinical study evaluating Deramiocel in Duchenne muscular dystrophy. HOPE-3 met its primary endpoint and key cardiac secondary endpoint, with all Type 1 error–controlled secondary endpoints also achieving statistical significance. Deramiocel maintained a favorable safety and tolerability profile consistent with prior studies. We are grateful to the patients, families, investigators and partners who made this milestone possible. Read the full announcement: bit.ly/3Ko9KV6 Join our conference call and webcast today at 8:00 a.m. ET. bit.ly/48O3SOb $CAPR #Duchenne #DMD #Deramiocel #HOPE3 #CellTherapy #RareDiseaseAdvocate

On Veterans Day, we pause to honor the courage, sacrifice, and service of our nation’s veterans, and the families who stand beside them. Your commitment inspires us to pursue life-changing science with purpose every day. Thank you for your service. $CAPR #VeteransDay #ThankYouVeterans

We just released our third quarter 2025 financial results and provided a corporate update. Click here to read the release:bit.ly/43X4fD9 $CAPR #DMD #deramiocel